Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: dupilumab
DRUG: Matching Placebo
DRUG: ICS/LABA

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]